China SXT Pharmaceuticals
SXTC
7 hedge funds and large institutions have $491K invested in China SXT Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
270% more capital invested
Capital invested by funds: $133K → $491K (+$358K)
250% more funds holding
Funds holding: 2 → 7 (+5)
0.2% more ownership
Funds ownership: 0.07% → 0.27% (+0.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$138K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$79K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$79K |
| 4 |
Renaissance Technologies
New York
|
+$79K |
| 5 |
HF
HRT Financial
New York
|
+$39.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$98.8K |
SXTC Hedge Fund Activity: Q3 2025 in Review
7 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q3 2025, worth a combined $491K — up 270% from $133K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SXTC positions and 1 closed out — a net gain of 5 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $138K. The largest seller was UBS Group, exiting entirely with an estimated $98.8K sold.
- 7 institutional investors held China SXT Pharmaceuticals (SXTC) as of Q3 2025, up from 2 in Q2 2025.
- Funds reported $491K of China SXT Pharmaceuticals stock for Q3 2025, up 270% quarter-over-quarter.
- 6 funds opened new China SXT Pharmaceuticals positions in Q3 2025 and 1 closed out, a net change of +5 holders.
- The largest China SXT Pharmaceuticals buyer in Q3 2025 was Invesco, an estimated $138K added.
- The largest China SXT Pharmaceuticals seller in Q3 2025 was UBS Group, an estimated $98.8K sold.
Based on aggregated 13F filings for Q3 2025.